Yu Jiang

Yu Jiang


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2024 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
XLXiang Li
Xiang Li
HXHaojun Xiong
Haojun Xiong
XMXingzhu Mou
Xingzhu Mou
CHCancan Huang
Cancan Huang
ETElizabeth Rosalind Thomas
Elizabeth Rosalind Thomas
YCYan Chen
Yan Chen
Prostate cancer (PCa) is witnessing a concerning rise in incidence annually, with the androgen receptor (AR) emerging as a pivotal contributor to its growth and progression. Mounting evidence underscores the AR's ability to recruit cofactors, influencing downstream gene transcription and thereby fueling the proliferation and metastasis of PCa cells. Although, clinical strategies involving AR antagonists provide some relief, managing castration resistant prostate cancer (CRPC) remains a formidable challenge. Thus, the need of the hour lies in unearthing new drugs or therapeutic targets to effectively combat PCa. This review encapsulates the pivotal roles played by coactivators and corepressors of AR, notably androgen receptor-associated protein (ARA) and steroid receptor Coactivators (SRC) in PCa. Our data unveils how these cofactors intricately modulate histone modifications, cell cycling, SUMOylation, and apoptosis through their interactions with AR. Among the array of cofactors scrutinised, such as ARA70β, ARA24, ARA160, ARA55, ARA54, PIAS1, PIAS3, SRC1, SRC2, SRC3, PCAF, p300/CBP, MED1, and CARM1, several exhibit upregulation in PCa. Conversely, other cofactors like ARA70α, PIASy, and NCoR/SMRT demonstrate downregulation. This duality underscores the complexity of AR cofactor dynamics in PCa. Based on our findings, we propose that manipulating cofactor regulation to modulate AR function holds promise as a novel therapeutic avenue against advanced PCa. This paradigm shift offers renewed hope in the quest for effective treatments in the face of CRPC's formidable challenges.

1 January 2025 in Journal of Stroke and Cerebrovascular Diseases
Verified
Journal Article
Open access
LHLinrong He
Linrong He
RLRuolan Lei
Ruolan Lei
SLShuang-Yang Li
Shuang-Yang Li
XZXiaoying Zhao
Xiaoying Zhao
XHXinying He
Xinying He
YJYu Jiang
Yu Jiang
Hirudin has shown potential in promoting angiogenesis and providing neuroprotection in ischemic stroke; however, its therapeutic role in promoting cerebrovascular angiogenesis remains unclear. In this study, we aimed to investigate whether hirudin exerts neuroprotective effects by promoting angiogenesis through the regulation of the Wnt/β-catenin signaling pathway. An in vitro model of glucose and oxygen deprivation/reperfusion (OGD/R) was established using rat brain microvascular endothelial cells (BMECs). The effects of hirudin on OGD/R cell viability were assessed using the cell counting kit-8 (CCK-8) assay. The angiogenic potential of hirudin was evaluated using Transwell and tube formation assays. In vivo, a middle cerebral artery occlusion/reperfusion (MCAO/R) model was created in rats. The neuroprotective effects of hirudin were assessed using the modified neurological severity score (mNSS), Hematoxylin and eosin (H&E) staining, 2,3,5-Triphenyltetrazolium chloride (TTC) staining, and immunofluorescence staining. Dickkopf-1 (DKK1), a specific inhibitor of this pathway, was introduced in order to investigate the role of the Wnt/β-catenin pathway. The effects of hirudin on the Wnt/β-catenin pathway were examined through immunohistochemistry, western blotting, and reverse transcription quantitative polymerase chain reaction (RT-qPCR). Hirudin significantly improved BMEC survival and enhanced both cell migration and tube formation in the OGD/R model. In the MCAO/R model, hirudin reduced the mNSS score, alleviated pathological damage, decreased infarction volume, and increased the expression of key angiogenic factors, including CD34, vascular endothelial growth factor (VEGF), and angiopoietin-2 (Ang-2). In addition, hirudin activated the Wnt/β-catenin pathway, leading to elevated levels of Wnt3a and β-catenin. Hirudin has substantial neuroprotective effects associated with the promotion of angiogenesis in the ischemic penumbra. This mechanism is mediated by the regulation of the Wnt/β-catenin pathway.

8 February 2025 in International Immunopharmacology
Verified
Journal Article
Open access
XZXiaoying Zhao
Xiaoying Zhao
YFYihua Fan
Yihua Fan
JSJiya Sun
Jiya Sun
HCHuixin Chen
Huixin Chen
ENEbuka-Olisaemeka Nwafor
Ebuka-Olisaemeka Nwafor
YJYu Jiang
Yu Jiang
The present study aimed to comprehensively assess the efficacy and safety of Chinese herbal compounds in the management of acute gouty arthritis (AGA). A systematic search was performed across multiple databases, including PubMed, The Cochrane Library, Embase, Web of Science, CBM, CNKI, VIP, and Wanfang, from their inception until December 1, 2024, to identify relevant randomized controlled trials (RCTs) involving Chinese herbal compounds for AGA. Two independent researchers were responsible for the retrieved literature screening, data extraction, and quality evaluation. A meta-analysis of RCTs that fulfill the inclusion criteria will be executed utilizing Stata 14.0 software. The quality of the outcomes will be assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE). A total of 28 studies, encompassing 2100 participants, were included in the analysis. The meta-analysis showed that compared with conventional Western medicine, Chinese herbal compounds significantly enhance the overall efficacy of AGA treatment (RR = 1.11, 95 %CI (1.05, 1.16), P < 0.00001; Level of evidence: very low). It also demonstrated improvements in the Visual Analogue Scale (VAS) (SMD = -1.46, 95 %CI(-2.17, -0.75), P < 0.00001; Level of evidence: very low), serum uric acid levels (SMD = -0.67, 95 %CI (-1.00, -0.33), P < 0.00001; Level of evidence: very low), blood sedimentation levels (SMD = -0.71, 95 %CI (-1.08, -0.33), P < 0.00001; Level of evidence: very low), C-reactive protein (CRP) levels (SMD = 0.89, 95 %CI(-1.33, -0.45), P < 0.00001; Level of evidence: very low), and the traditional Chinese medicine syndrome score(SMD = -0.93, 95 %CI (-1.37, -0.49), P < 0.00001; Level of evidence: very low). Additionally, a reduced incidence of adverse effects was noted (RR = 0.26, 95 %CI (0.18, 0.39), P < 0.00001; Level of evidence: moderate). Subgroup analysis revealed that regardless of whether the treatment duration was less than or more than 1 week, Chinese herbal compounds were effective in improving the total effective rate of AGA treatment, VAS scores, serum uric acid levels, blood sedimentation levels, CRP levels, and Traditional Chinese medicine symptom scores, while simultaneously decreasing the occurrence of adverse reactions. Chinese herbal compounds demonstrated superior efficacy and safety compared to conventional Western medicine in treating AGA. However, further validation through multicenter, high-quality RCTs is warranted to strengthen this conclusion.

28 September 2022 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
XYXin Yang
Xin Yang
王L王龙 Wang, Long
王龙 Wang, Long
JZJing Zeng
Jing Zeng
WAWu An-Guo
Wu An-Guo
MQMi Qin
Mi Qin
WJWu Jianming
Wu Jianming
Thrombocytopenia is one of the most common complications of cancer therapy. Until now, there are still no satisfactory medications to treat chemotherapy and radiation-induced thrombocytopenia (CIT and RIT, respectively). Caulis Polygoni Multiflori (CPM), one of the most commonly used Chinese herbs, has been well documented to nourish blood for tranquilizing the mind and treating anemia, suggesting its beneficial effect on hematopoiesis. However, it is unknown whether CPM can accelerate megakaryopoiesis and thrombopoiesis. Here, we employ a UHPLC Q–Exactive HF-X mass spectrometer (UHPLC QE HF-X MS) to identify 11 ingredients in CPM. Then, in vitro experiments showed that CPM significantly increased megakaryocyte (MK) differentiation and maturation but did not affect apoptosis and lactate dehydrogenase (LDH) release of K562 and Meg-01 cells. More importantly, animal experiments verified that CPM treatment markedly accelerated platelet recovery, megakaryopoiesis and thrombopoiesis in RIT mice without hepatic and renal toxicities in vivo. Finally, RNA-sequencing (RNA-seq) and western blot were used to determine that CPM increased the expression of proteins related to PI3K/Akt and MEK/ERK (MAPK) signaling pathways. On the contrary, blocking PI3K/Akt and MEK/ERK signaling pathways with their specific inhibitors suppressed MK differentiation induced by CPM. In conclusion, for the first time, our study demonstrates that CPM may be a promised thrombopoietic agent and provide an experimental basis for expanding clinical use.

13 May 2025 in Digestive and Liver Disease
Verified
Journal Article
Closed access
RLRuo-Lan Lei
Ruo-Lan Lei
XZXiao-Ying Zhao
Xiao-Ying Zhao
LHLin-Rong He
Lin-Rong He
YJYu Jiang
Yu Jiang

5 November 2025 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
XZXiaoying Zhao
Xiaoying Zhao
XYXinyue Yang
Xinyue Yang
YLYumeng Lin
Yumeng Lin
RLRuolan Lei
Ruolan Lei
WDWei Ding
Wei Ding
YJYu Jiang
Yu Jiang
Cardiovascular diseases (CVDs) pose a significant threat to the health of the elderly population. As the global population ages and medical management remains imperfect, reducing the medical burden of CVDs is of great importance. Aging is a complex process that contributes to the development and progression of CVDs through various mechanisms. The manuscript reviews the mechanisms of aging and their impact on the cardiovascular system. We explore the role of aging in the cardiac microenvironment, highlighting the changes that occur in the heart’s cellular and molecular landscape as a result of the aging process.